Compare LPG & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPG | CRVS |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2014 | 2016 |
| Metric | LPG | CRVS |
|---|---|---|
| Price | $38.41 | $14.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $39.33 | $30.17 |
| AVG Volume (30 Days) | 384.5K | ★ 1.1M |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.32% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ 2.64 | N/A |
| Revenue | ★ $353,341,476.00 | N/A |
| Revenue This Year | $35.73 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.60 | $3.17 |
| 52 Week High | $39.00 | $26.95 |
| Indicator | LPG | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 66.72 | 43.64 |
| Support Level | $29.47 | $14.38 |
| Resistance Level | N/A | $19.21 |
| Average True Range (ATR) | 1.29 | 1.21 |
| MACD | 0.28 | -0.03 |
| Stochastic Oscillator | 83.55 | 6.62 |
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece. IT operates in one reportable segment, the international transportation of LPG.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.